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Abstract 
Philadelphia chromosome-positive (Ph+) leukemia is characterized by reciprocal translocation 
between chromosomes 9 and 22. The resultant BCR/ABL fusion protein displays constitutive 
tyrosine kinase activity, leading to the induction of aberrant proliferation and neoplastic 
transformation. The bone marrow (BM) microenvironment is tumor-promoting, and contributes 
to disease recurrence in Ph+ leukemia. Activity in the BM microenvironment is mediated by 
several cellular compartments, extracellular matrix, various soluble factors including transforming 
growth factor beta 1 (TGF-β1), and the hypoxic conditions in the BM niche. TGF-β1 is released 
during bone remodeling and plays a role in maintaining leukemic stem cells, as well as being 
implicated in the epithelial–mesenchymal transition (EMT) process in most solid tumors. Although 
EMT is largely implicated in epithelial tumors, recent findings argue for an EMT-like process in 
leukemia as well. The surface receptor CD44 is involved in cell adhesion, cell migration, and 
homing of normal and malignant hematopoietic stem cells. Elevation of CD44 expression is 
considered a marker for a worse prognosis in most hematological malignancies. We explored the 
functions of Snail and Twist1 in Ph+ leukemia. We showed that ectopic expression of Snail and, to 
a lesser extent, Twist1, upregulates CD44 expression that is β-catenin-dependent. Moreover, the 
presence of Snail or Twist1 partially blocked phorbol 12-myristate 13-acetate-induced 
megakaryocyte differentiation, while that of Twist significantly altered imatinib-induced erythroid 
differentiation. Thus EMT modulators affected proliferation, CD44 gene expression and 
differentiation ability of Ph+ leukemia cells. 
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Introduction 
Philadelphia chromosome-positive (Ph+) 
leukemia is characterized by the t(9;22) chromosome 
translocation that creates the BCR/ABL oncogene. 
This fusion protein displays constitutive tyrosine 
kinase activity, leading to the induction of aberrant 
proliferation and neoplastic transformation. The Ph+ 
chromosome is found in more than 95% of chronic 
myeloid leukemia (CML) and in Ph+ acute 
lymphoblastic leukemia. Activation of BCR/ABL 
increases proliferation, reduces susceptibility to a 
variety of proapoptotic stimuli—including growth 
factor deprivation—and leads to neoplastic 
transformation [1].  
ABL kinase inhibitors (AKIs) are utilized for the 
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treatment of Ph+ leukemia. The initial response is 
good [2-4] but unfortunately, the clinical efficacy of 
this treatment decreases continuously as the disease 
advances. Blast crisis (BC) CML or Ph+ acute 
lymphoblastic leukemia patients only benefit from 
AKI treatment temporarily, if at all [5]. Moreover, 
despite the remarkable success of AKIs against Ph+ 
leukemia, these drugs do not seem to cure the disease. 
This seems to be due to their failure to reliably 
eliminate the Ph+ leukemia stem cells (LSCs) [6]. 
Interestingly, an increasing number of reports 
demonstrate that LSCs of Ph+ leukemia are 
dependent on BCRABL protein and not on its kinase 
activity, explaining the AKIs' inability to eradicate 
LSCs and eliminate residual disease [7-9].  
The bone marrow (BM) microenvironment plays 
a significant role in the etiology of Ph+ leukemia. In 
addition, cellular adhesion of Ph+ leukemia cells to 
stromal cells and extracellular components within the 
BM niche, as well as exposure to soluble factors such 
as growth factors and interleukins, contribute to 
residual disease. 
The epithelial–mesenchymal transition (EMT) 
encompasses a series of events leading to acquisition 
of motile migratory properties. It has been shown that 
factors regulating the development of EMT play roles 
in tumor progression, including TGF-β-, Wnt-, and 
Notch-signaling pathways, as well as Snail1, Slug, 
Zeb1, Twist1, and others. Although the EMT has been 
studied in relation to epithelium-derived tumors, 
increasing evidence implicates EMT activators, 
especially Snai/Zeb families, in hematopoietic 
malignancies [10]. Analysis of samples from CML 
patients during disease progression revealed 
upregulation of Twist1, which correlated with AKI 
drug resistance, without any detectable resistance 
mechanism. This argues for the potential involvement 
of Twist1 in CML resistance and disease progression 
[11]. Moreover, Slug contributes to apoptosis 
resistance, prolonged survival, and imatinib 
resistance of CML progenitors [12]. Long-term 
treatment with imatinib triggers a mesenchymal-like 
conversion of CML cells accompanied by increased 
aggressiveness and associated with increased 
EMT-like phenotypes, adhesion and invasion [13]. 
Moreover, Slug overexpression has been reported to 
be essential for the homing of CML cells to the BM 
[14].  
CD44 is a cell-surface receptor for hyaluronic 
acid, involved in cell adhesion, cell matrix interaction 
and cell migration, and functioning as a "BM homing 
receptor" by directing migration of human and mouse 
stem cells to the BM [15, 16]. Moreover, altered CD44 
expression functions as a marker for worse prognosis 
in most hematological malignancies; expression of 
particular isoforms of CD44 has been associated with 
malignant transformation and/or the acquisition of 
metastatic potential. CD44 has also been implicated in 
LSCs, and its expression increases in several types of 
leukemia. Furthermore, CD44 expression increases in 
mouse stem/progenitor cells expressing BCR/ABL 
and involved in regulating LSC homing and 
engraftment. 
In this study, we investigated the function of 
ectopically expressed Snail and Twist1 in Ph+ 
leukemia cell lines and monitored changes in the 
expression levels of cell-surface markers involved in 
cell migration and BM homing. Our data showed that 
ectopic expression of Snail significantly upregulates 
CD44 in a β-catenin-dependent manner. Moreover, 
ectopic expression of Twist1 and Snail compromised 
the ability of phorbol 12-myristate 13-acetate (PMA) 
to induce megakaryocyte differentiation, and ectopic 
expression of Twist1 had a limited effect on 
imatinib-induced erythroid differentiation.  
Materials and Methods 
Cell lines and cell culture 
Breast cancer cell lines MCF7 and MDA-MB-231, 
and Ph+ leukemia cell lines K562, MEG-01, SupB-15, 
BV-173 and murine mesenchymal cells (MS-5) were 
obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA) and cells were grown in 
RPMI 1640 (Sigma, Rehovot, Israel) containing 2 mM 
L-glutamine, 10% (v/v) fetal bovine serum (FBS), and 
100 IU/ml penicillin and 100 μg/ml streptomycin 
(PenStrep; Biological Industries, Beit Haemek, Israel). 
The human embryonic kidney cell line 293T 
(HEK293T) was obtained from ATCC and maintained 
in Dulbecco's Modified Eagle Medium (DMEM; 
Sigma) supplemented with 10% (v/v) fetal calf serum 
(FCS), 2 mM L-glutamine, 1 mM sodium pyruvate, 
and 1% (w/v) PenStrep. All cell lines were grown at 
37oC in a humidified atmosphere with 5% CO2.  
Trypan blue exclusion assay 
Cells were plated in 6-well plates (3 x 105 
cell/well) containing 3 ml of complete medium. Cells 
viability were monitored on day 1,2,3 and 4 after cell 
plating by collecting samples from the cell cultures 
followed by staining with 0.25% (w/v) trypan blue 
solution (1:1 v/v), and counting using a 
hemocytometer. 
Construction of K562 cells overexpressing 
Snail and Twist1 proteins 
K562 cells were infected with retrovirus carrying 
either Snail-ER (Snail fused to ligand binding domain 
of estrogen receptor) (pWZL Blast Snail ER, Addgene 
plasmid #18798) or Twist1-ER constructs (pWZL Blast 
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Twist ER, Addgene plasmid #18799). Both plasmids 
were a gift from Bob Weinberg [17]. The ER included 
in both constructs carried the G525R mutation, which 
abrogates its binding to 17β-estradiol while retaining 
its full sensitivity to the synthetic ligand 
4'-hydroxytamoxifen. Infected cells were selected for 
resistance to blasticidin and were validated for the 
presence of Snail or Twist by RT-PCR and 
immunoblotting using anti-ERα antibodies. 
Adhesion of K562 cells to murine 
mesenchymal cells (MS-5) 
Luciferase reporter plasmid (CMV-Luci) was 
transfected into K562 cells using electroporation. 
MEG-01 cells were used as a positive control in this 
experiment. Next day, luciferase levels were 
determined and cell aliquots were added to empty 
wells or to wells containing MS-5 cells. Two hours 
later, wells were washed 6 times with PBS and levels 
of remaining luciferase levels were determined. 
Signals obtained from wells containing MS-5 were 
considered as specific adhesion signals, while signals 
obtained from wells that devoted of MS-5 cells were 
considered as non-specific signal.  
Western blot analysis 
Immunoblotting was performed as previously 
described [18]. Briefly, different cells were inoculated 
into flasks and 48 h later, cell lysates were prepared 
and subjected to electrophoresis on an 8% 
SDS-polyacrylamide gel and western immunoblotting 
with the appropriate antibodies. The antibodies used 
in this study were rabbit polyclonal β-catenin (Cell 
Signaling Technologies, Danvers, MA, USA), mouse 
monoclonal α-tubulin (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), rabbit polyclonal ER (Santa 
Cruz Biotechnology), rabbit monoclonal Snail (Cell 
Signaling Technologies), rabbit monoclonal phospho 
c-ABL (Tyr 245) (Cell Signaling Technologies) and 
mouse monoclonal c-ABL (24-11) (Santa Cruz 
Biotechnology).  
Erythroid Differentiation of K562 cells 
K562 cells were stimulated with imatinib to 
undergo erythroid differentiation [19] as previously 
described [20]. Briefly, erythroid differentiation was 
determined by monitoring levels of γ-globin 
expression in treated cells by real-time PCR. K562 
cells were plated in 6-well plates (2 x 105 cell/ml), 
followed by treatment with 0.4 µM imatinib for 6 
days. Cells were collected and total RNA was isolated 
using Tri Reagent (Sigma). Levels of γ-globin were 
monitored by real-time PCR and normalized to levels 
of β-actin. Primer sequences and annealing 
temperatures are provided in Supplemental Table S1.  
Megakaryocyte differentiation of K562 cells 
K562 cells were stimulated with PMA to 
undergo megakaryocyte differentiation. Megakaryo-
cyte differentiation was determined by monitoring 
levels of CD41 and CD61 in treated cells [19]. K562 
cells were plated in 6-well plates (2 x 10 5 cell/ml), and 
treated with 5 ng/ml PMA for 6 days. Cells were 
collected, washed with PBS and subjected to FACS 
analysis using CD61 PC7 (#IM3716, Beckman 
Coulter, Nyon, Switzerland) and CD41 fluorescein 
isothiocyanate (FITC) (#9011-0419, eBioscience, 
Emeryville, CA, USA).  
Silencing of β-catenin in K562 cells 
The β-catenin gene was silenced in K562 cells 
(K562, K562/Twist1 and K562/Snail) as previously 
described [21]. Briefly, β-catenin shRNA plasmid 
DNA (pLKO.1 puro shRNA β-catenin Addgene 
plasmid # 18803) [22], pcMV-dR8.2 dvpr and 
pcMV-VSV-G (Addgene plasmid #8455 and #8454, 
respectively) [23] were gifts from Bob Weinberg. 
These were co-transfected into HEK239T cells at 1.5 x 
105 cell/ml using Fugene 6 (Roche Applied Science, 
Penzberg, Germany) according to the manufacturer's 
instructions. The supernatant of the infected cells was 
collected 48 h post-transfection, used to infect the 
selected K562 cells lines, and puromycin-resistant 
clones were selected. Levels of β-catenin transcript 
and protein were monitored using real-time PCR and 
immunoblotting, respectively. 
Cellular autophosphorylation of BCR/ABL 
Cellular autophosphorylation assay was used to 
monitor levels of phosphorylated BCRABL in treated 
cells following the ELISA format. Briefly, cells from 
the various K562 cell lines (4 x 105 cell/ml) were 
treated with imatinib for 1 h at the specified 
concentrations. Cells were collected, washed 
twice with cold PBS, and lysed in 1X cell lysis buffer 
(Cell Signaling Technologies). Using clear flat-bottom 
immuno nonsterile 96-well plates (Thermo Fisher 
Scientific), wells were coated with 50 ng/well of 
mouse monoclonal c-ABL (24-11) and incubated 
overnight at room temperature (RT). The next day, 
wells were washed five times with PBS + 0.05% (w/v) 
Tween 20 and blocking buffer (3% w/v bovine serum 
albumin [BSA] in PBS) was added for 2 h at RT. Next, 
wells were washed five times, 100 µg/well of cell 
lysate was diluted in 1% (w/v) NP-40, 20 mM Tris 
(pH 8.0), 137 mM NaCl, 10% (w/v) glycerol, 2 mM 
EDTA and 1 mM activated sodium orthovanadate, 
and plates were incubated at 4oC overnight. After 
washing as before, 50 ng/well of PY20 antibody 
(anti-pTyr conjugated to HRP; Santa Cruz 
Biotechnology) diluted in 0.1% BSA, 20 mM Tris, 137 
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mM NaCl, 0.05% Tween 20, pH 7.2–7.4 was added for 
2 h at RT, followed by five washes and incubation 
with SIGMAFAST OPD (Sigma-Aldrich, St. Louis, 
MO, USA) for 30 min. Optical density was determined 
at 450 nm. 
Flow cytometric analysis 
A variety of Ph+ leukemia cells and K562 cells 
carrying either Snail or Twist1 were re-suspended in 
PBS plus 0.5% BSA to a density of 1 × 107 cell/ml. 
Antibodies against CD34 PE (#IM1459u, Beckman 
Coulter), CD117 PCy7 (#IM3698, Beckman Coulter), 
CD45 KRO (#A96416, Beckman Coulter), CD61 PC7 
(#IM3716, Beckman Coulter), CD41 FITC (#9011-0419, 
eBioscience), CD44 FITC (#F7083, DAKO, Denmark), 
CD44 FITC (#9011-0441, eBioscience) and CD184 APC 
(#FAB173A, R&D Systems, Minneapolis, MN, USA ) 
were titrated for use or added at the volumes 
suggested by the manufacturer and the mixture was 
incubated on ice for 40 min. After washing with PBS 
and 0.5% BSA, the labeled cells were analyzed on a 
Beckman Coulter Navios cytometer. 
Immunofluorescence 
K562 cells (1 x 106) were washed twice with 
0.05% Tween 20 in PBS, fixed with 4% 
paraformaldehyde for 10 min, washed with 0.05% 
Tween 20 in PBS and incubated in saponin buffer (Cell 
Signaling Technologies) for 15 min. Cells were 
blocked with 5% BSA in PBS for 30 min. at RT 
followed by incubation with a 1:50 dilution of primary 
rabbit anti-Snail antibody (Cell Signaling 
Technologies) for 30 min. at RT. Next, secondary 
donkey anti-rabbit–FITC antibody (Santa Cruz 
Biotechnology) was added at a 1:50 dilution and 
incubated for 30 min. at 4oC. Fluorescence levels were 
measured by Becton Dickinson FACS caliber using 
FCS express De Novo software. To localize Snail, K562 
cells were incubated with Hoechst solution at a 1:5000 
dilution for 3 min, followed by three washes (0.05% 
Tween 20 in PBS), and were observed under a 
confocal microscope (Zeiss, LSM700) at 20X 
magnification. Pictures were analyzed by Zen 
software.  
Semi-quantitative RT-PCR 
RT-PCR analysis was performed as previously 
described [24]. Total RNA was extracted from the cells 
using Tri Reagent (Sigma). Single-stranded cDNA 
was synthesized from the total RNA. Briefly, 1 μg 
RNA was preincubated with 1 μl oligo(dT)17 primer, 
and diethylpyrocarbonate (DEPC)-treated water was 
added to a total volume of 15 μl at 70oC for 10 min, 
then the mixture was rapidly chilled on ice. To the 
annealed primer/template, 2 µl AMV RT 5X reaction 
buffer, 2 µl dNTP (25 mM), 28 units of RNasin 
ribonuclease inhibitor, 30 units of AMV RT, and 
DEPC-treated water were added to a final volume of 
10 µl. The reaction was incubated at 42oC for 60 min. 
The resulting cDNA was amplified with a PCR kit 
(Bioline, Taunton, MA, USA). The primer sets used for 
each gene are listed in Supplemental Table S1. A total 
of 35 cycles of amplification were performed with an 
initial incubation at 94oC for 2 min and a final 
extension at 72oC for 15 min; each cycle consisted of 
denaturation at 94oC for 30 s, annealing at 55–60oC for 
30 s and an extension at 72oC for 2:30 min. To ensure 
the use of equal amounts of cDNA from each sample 
in the PCR, the aliquots of the reverse transcription 
products were used with primers for the 
housekeeping gene β-actin. A total 5 µl of the PCR 
products was analyzed by electrophoresis on a 1.5% 
agarose gel. 
Quantitative real-time RT-PCR 
Total RNA extraction and reverse transcription 
were performed as described for the semi-quantitative 
RT-PCR. The cDNA of the mRNA transcripts was 
amplified by real-time quantitative PCR in a 15-μl 
reaction mixture containing 0.2 pmol/µl 
forward/reverse primers and 1X SYBR GREEN 
reaction mix (Kappa Biosystems, Wilmington, MA, 
USA). The reaction was performed in a 
spectrofluorometric thermal cycler (Rotor-GeneTM 
6000, Corbett Research, Mortlake, Australia), with 
preliminary denaturation for 10 min at 95oC to 
activate Taq DNA polymerase, followed by 55 cycles 
of denaturation at 95oC for 15 s, and 
annealing/extension at 55–60oC for 1 min 
(Supplemental Table S1). Different amounts of 
template were used in the same reaction to ensure 
linear amplification of PCR products. The β-actin gene 
was used as an internal control amplified in the same 
PCR assay. The primer sets were the same as those 
used in the semi-quantitative RT-PCR (Supplemental 
Table S1). 
Statistical analysis 
Statistical analysis was performed using 
Student’s t-test with significance values set at *P < 0.01 
or **P < 0.001. 
Results 
Expression levels of EMT modulators in Ph+ 
leukemia cell lines 
Puissant et al. [13] described an EMT-like 
phenotype of Ph+ leukemia cells that was associated 
with increased adhesion and invasion. Moreover, 
EMT modulator (Slug) expression has been reported 
to be essential for the homing of Ph+ leukemia cells to 
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the BM [14]. We therefore monitored the expression 
levels of EMT modulators in Ph+ leukemia cell lines 
by RT-PCR. As a control, we monitored their 
expression levels in MDA-MB-231 (mesenchymal) 
and MCF7 (epithelial) breast cancer cells. As expected, 
EMT modulators were expressed at high levels in 
MDA-MB-231 cells and at very low levels in MCF7 
cells (Figure 1). EMT modulators were also expressed 
in Ph+ leukemia cells lines at varying levels: Twist1 
was expressed at low levels, and Zeb1 at high levels in 
all Ph+ leukemia cells; Snail was expressed at 
comparable levels in K562 and MEG-01 cells, but its 
expression was low in SupB15 and BV173 cells. 
Interestingly, Slug was expressed at high levels in 
MEG-01 but was undetectable in the other Ph+ 
leukemia cell lines. 
Since the EMT modulators were expressed in 
Ph+ leukemia cells at various levels, and expression of 
some of them (Snail and Zeb1) was comparable to that 
found in breast cancer cells, it was reasonable to 
speculate that the presence of EMT modulators might 
also be of significance in Ph+ leukemia. 
Expression of the cell-surface markers CD44 
and CXCR4 in Ph+ leukemia cell lines 
Ph+ LSC homing and engrafting in the BM 
contribute to residual disease. Homing and engrafting 
in Ph+ leukemia is mediated, in part, by CD44 and 
CXCR4 surface proteins which have been previously 
implicated in the etiology of Ph+ leukemia [25]. We 
therefore monitored the expression levels of CD44 
and CXCR4 (CD184) using FACS analysis and 
RT-PCR. Results, summarized in Table 1, 
demonstrated that CD44 and CXCR4 are expressed at 
very low levels in K562 cells (Figure 2A); in MEG-01 
cells, their expression was significantly higher (Table 
1, Figure 2, Supplemental Figure S1). Levels of CD44 
were also high in Ph+ leukemia cell lines BV173 and 
SupB15 (Table 1). Interestingly, BV173 and SupB15 
cells also expressed high levels of CXCR4 compared to 
the low levels in K562 and MEG-01 cell lines (Table 1, 
Supplemental Figure S2). RT-PCR analysis of CD44 
and CXCR4 transcripts in the different cells (Figure 
2B) was in agreement with the data presented in Table 
1. Transcript levels of CD44 in the different Ph+ 
leukemia cells were also monitored, and CD44 levels 
were high in all cell lines tested except MCF7 and 
K562 (Figure 2B). On the other hand, transcript levels 
of CXCR4 were high in BV173, SupB15 and 
MDA-MB-231 cell lines, low in MEG-01 and K562 cell 
lines, and moderate in MCF 7 cell lines (Figure 2B). 
 
Table 1. Expression levels of CXCR4 and CD44 in 
Ph-positive leukemia cells: Levels of CXCR4 and CD44 in 
Ph-positive cells were determined using FACS analysis.  
Ph+ leukemia cell lines % of positive cells for 
CD44 CXCR4 
K562 3.4 0.8 
MEG-01 99.6 3.3 
BV173 98.7 99.4 
SupB15 64.1 96.7 
 
 
Figure 1. Expression levels of EMT modulators in Ph-positive leukemia cells: Expression levels of EMT modulators in Ph+ leukemia cells in comparison to 
MCF7 (epithelial) and MDA-MB-231 (mesenchymal) breast cancer cells were determined by RT-PCR.  
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Figure 2. Expression levels of CD44 and CXCR4 in Ph-positive leukemia cells: (A) FACS analysis of CD44 expression in CML cells. (B) RT-PCR analysis of 
CD44 and CXCR4 expression in Ph+ leukemia cell lines. 
 
Ectopic expression of Twist1 and Snail in Ph+ 
leukemia cells 
To explore the activity of EMT modulators in 
regulating CD44 and CXCR4 expression, we 
expressed them ectopically in Ph+ leukemia cell lines. 
For this study, we selected K562 cells which express 
low levels of both surface receptors (Table 1 and 
Figure 2) relative to other Ph+ leukemia cell lines. The 
expression vectors of Snail and Twist1 were 
introduced into K562 Ph+ leukemia cells and their 
expression was monitored (Figure 3). The EMT 
modulators used in this study lacked the endogenous 
3' untranslated region of the appropriate genes to 
escape microRNA regulation [26]. Expression was 
validated by RT-PCR (Supplemental Figure S1), 
immunoblotting (Figure 3A) and FACS (Figure 3B). 
Snail expression was localized to two compartments, 
the nucleus and the cytoplasm (Figure 3B). Next, we 
monitored the proliferation of K562 cells carrying 
Snail or Twist1 in comparison to the parental K562 
cells. The presence of Snail and Twist1 conferred 
enhanced proliferation ability to K562 cells (Figure 
3C), consistent with the finding of enhanced 
proliferation of BC CML cells [27]. Moreover, there 
was no difference in the levels of BCR/ABL or 
phosphorylated BCR/ABL in K562 cells harboring 
either Snail or Twist1 (Figure 3D). Finally, the 
presence of Snail or Twist1 did not affect drug 
sensitivity to imatinib as determined by monitoring 
BCR/ABL auto-phosphorylation at different imatinib 
concentrations (Figure 3D). 
Expression of cell-surface markers in Ph+ 
leukemia cells ectopically expressing Snail or 
Twist1 
K562 cells ectopically expressing Snail or Twist1 
were exposed to 20 nM 4-hydroxytamoxifen (4-OHT) 
for 2 weeks [17] to activate the two proteins, and 
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levels of CD44 and CXCR4 were monitored by 
real-time PCR and FACS analyses. Our results, shown 
in Figure 4A and 4B, demonstrated low levels of CD44 
expression in K562 cells relative to the significantly 
higher expression in SupB15 cell lines. However, the 
relative level of CD44 expression was significantly 
increased in K562 cells expressing activated Snail, by 
more than 10-fold (Figure 4A-4B). Interestingly, the 
presence of activated Twist1 in K562 cells caused only 
a marginal increase in CD44 levels. Moreover, FACS 
analysis of K562 cells harboring activated Snail or 
Twist1 for 4 weeks showed 55.5% and 11.2% of the 
cells, respectively, as positive for CD44 expression, 
compared to 1% in parental K562 cells (Figure 4C-4D). 
Interestingly, the percentage of CD44-positive K562 
cells overexpressing Snail or Twist1 increased with 
duration of activation with 4-OHT. Supplemental 
Figure S3 shows increasing percentages of 
CD44-positive cells after 1, 2 and 4 weeks of 
activation. 
CXCR4 expression levels were also monitored in 
K562 cells and compared to those in the other Ph+ 
leukemia cell lines. Expression levels of CXCR4 were 
very low in K562 and MEG-01 cells compared to high 
expression levels in BV173, SubB15 and the control 
cells (MD-MB-231 and MCF 7) (Figure 2). Next, we 
tested expression levels in K562 cells harboring Snail 
or Twist1: the presence of Snail or Twist1 did not 
cause any significant change in CXCR4 expression 
(Table 2). Although CXCR4 levels were very low in 
K562 and MEG-01 cells, ectopic expression of Twist1 
seemed to slightly upregulate its expression (Table 2). 
 
Table 2. Expression of CXCR4 in K562 ectopically 
expressing Twist1 and Snail: K562 cells were treated for 6–8 
weeks with 4-OHT and levels of CXCR4 were determined using 
FACS analysis. Levels of CXCR4 were also monitored in MEG-01 
cells. 
Cell % of CXCR4-positive cells 
K562 0.2 
K562/Snail 0.4 
K562/Twist1 1.1 
MEG-01 0.4 
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Figure 3. Ectopic expression of Snail and Twist1 in K562 cells: (A) Immunoblotting of cell lysates prepared from K562, K562/Snail and K562/Twist1 using 
anti-mouse ERα. (B) FACS analysis and confocal microscopy using anti-Snail antibody. (C) Proliferation of K562 cells ectopically expressing Snail or Twist1 using 
Trypan blue exclusion assay. (D) Immunoblotting with phosphor-ABL antibody to determine K562 cell sensitivity to imatinib. 
 
Snail overexpression also stimulated the 
expression of other cell-surface receptors, such as 
CD34 (7.4% compared to 1.2% in parental K562 cells) 
and slightly reduced the percentage of 
CD117-positive cells (from 6.3 in the parental K562 
cells to 3.3 in K562 cells ectopically expressing Snail). 
Twist1 overexpression had a different outcome: the 
percentages of CD34- and CD117-positive cells were 
0.5 and 5.9, respectively, compared to 1.2 and 6.3, 
respectively, in the parental cell line. Interestingly, 
longer exposure to 4-OHT (about 6–8 weeks) resulted 
in accumulation of cells that were positive for the 
different surface markers (Table 3). Of special interest 
is that the presence of Snail was more effective than 
that of Twist1 in stimulating CD34 expression, 
whereas Twist1 was more effective at inducing CD117 
expression (Table 3). Our findings for CD44 are 
consistent with a recent report showing enhanced 
homing to the BM of K562 cells ectopically expressing 
Slug protein [14], apparently due to upregulation of 
CD44. Taken together, ectopic expression of Snail, and 
to a lesser extent Twist1, enhanced the expression of 
CD44 and other surface markers that are associated 
with CML stemness (CD34 and CD117) and homing 
of human leukemia cells to the BM. 
Ectopic expression of Snail or Twist1 alters 
K562 cell line's ability to undergo erythroid 
and megakaryocyte differentiation 
One of hallmarks of advanced stage of Ph+ 
leukemia and in particular BC CML is blockage of 
differentiation [27]. We therefore determined whether 
ectopic expression of Snail or Twist1 would influence 
K562 cells' ability to undergo induced erythroid and 
megakaryocyte differentiations [19]. We utilized 
hemin, butyric acid [28] and imatinib to induce 
erythrocyte differentiation and monitored γ-globin 
expression [29] as an erythroid differentiation marker 
by real-time PCR. Exposure to low levels of imatinib 
induced erythroid differentiation as reflected by an 
over 10-fold increase in γ-globin expression (Figure 
5A and 5B). Similarly, imatinib induced erythroid 
differentiation in K562 cells ectopically expressing 
Snail to levels comparable to those of the parental 
K562 cells. Interestingly, K562 cells expressing Twist1 
induced even higher levels of γ-globin compared to 
parental K562 cells (a 2- to 3-fold increase) and K562 
cells ectopically expressing Snail.  
Next, we followed the ability of 1 ng/ml PMA to 
induce megakaryocyte differentiation by monitoring 
levels of the surface markers CD41/CD61 [30] by 
FACS. Most K562 cells exposed to PMA for 6 days 
were positive for CD61 (46.7%) and CD41/CD61 
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(43.7%) (Figure 5C and 5D). Similarly, PMA induced 
the expression of megakaryocyte markers in K562 
cells ectopically expressing Snail or Twist1, albeit at 
reduced efficacy. The presence of Snail or Twist1 
compromised PMA's ability to induce 
megakaryocytic differentiation in K562 cells [19], 
leading to a significant reduction in the percentage of 
cells that were CD61- or CD41-positive to 21.28 and 
18.63%, respectively, compared to parental K562 cells 
(43.7%). This suggested that the presence of Snail or 
Twist1 partially blocks megakaryocyte differentiation. 
Ectopic expression of Twist1 and Snail 
enhance adhesion to murine mesenchymal 
cells (MS-5) 
Our previous results showed significant impact 
of ectopic expression of Twist1 and Snail on the 
expression of surface molecules that in part mediate 
cell adhesion. Therefore, cell adhesion of K562 cells to 
murine mesenchymal cells (MS-5) was investigated. 
Results shown in Figure 6 illustrated that adhesion 
ability of MG-01 to MS-5 is greater compared to K562 
cells (Figure 6A). However, ectopic expression of Snail 
or Twist1 significantly augmented adhesion ability of 
K562 cells to mesenchymal cells (MS-5) by causing the 
increase specific adhesion to MS-5 to 30.75% and 
50.97% in the presence of Twist1 and Snail, 
respectively, compared to 5% in the parental K562 
cells (Figure 6B). This argues that presence of 
Snail/Twist1 stimulated the adhesion ability of K562 
cells that mediated by inducing the expression of 
CD44 and probably other adhesion molecules.  
Table 3. Expression of surface markers in K562 
ectopically expressing Twist1 and Snail: K562 cells were 
treated for 6–8 weeks with 4-OHT and levels of different surface 
markers were determined using FACS analysis. 
CD Marker K562 K562/Snail K562/Twist1 
CD44 1.6% 55.5% 11.2% 
CD41 0.8% 15.1% 1.8% 
CD34 0.9% 22.1% 16.4% 
CD117 2.3% 16.4% 51.1% 
CD61 2.8% 28.2% 3.6% 
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Figure 4. Snail and Twist1 stimulate CD44 expression in K562 cell lines: K562, K562/Twist1 and K562/Snail were treated with 4-OHT for 2 weeks and 
relative levels of CD44 (normalized to β−actin) were determined by real-time PCR (A). Quantitative and normalized data are shown (B). Levels of CD44 were also 
monitored by FACS analysis using CD45 and CD44 antibodies (C). (D) Percentage of CD44-positive cells. *, ** Significant difference at P < 0.01 and 0.001, 
respectively.  
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Snail-dependent upregulation of CD44 is 
β-catenin-dependent 
The protein β-catenin has been implicated in the 
regulation of CD44 expression [31]. We therefore 
explored the cross-talk between β-catenin and Snail in 
the observed Snail-dependent upregulation of CD44. 
We silenced β-catenin in K562, K562/Snail and 
K562/Twist1 cells. Our results showed that in all 
silenced β-catenin K562 cells, there was a significant 
reduction in the levels of β-catenin transcript (Figure 
7A). Silencing of β-catenin significantly abrogated 
Snail's ability to upregulate CD44, arguing that 
Snail-mediated upregulation of CD44 is 
β-catenin-dependent (Figure 7B and 7C, 
Supplemental Figure S4). Previous studies have 
shown that CD44 is also upregulated by PMA in 
monocytes [32]. Thus, we tested whether 
PMA-induced CD44 is also regulated by β-catenin. 
Results shown in Figure 7D demonstrated that in 
K562 cells, exposure to PMA is sufficient to 
significantly upregulate levels of CD44, with about 
90% of the cells being positive for CD44 compared to 
0.45% in the absence of PMA. However, silencing of 
β-catenin in K562 cells had no effect on PMA-induced 
CD44 expression, in contrast to the Snail-induced 
CD44 expression. Moreover, we monitored levels of a 
variety of surface markers in response to silencing of 
β-catenin (Table 4). 
Results presented in Table 4 show that silencing 
of β-catenin reduced Snail-induced expression of 
CD34, CD41 and CD61. In contrast, silencing of 
β-catenin in K562 cells harboring Twist1 exhibited 
only a marginal and nonsignificant effect on the 
expression levels of CD34, CD41 and CD61. However, 
silencing of β-catenin in K562 cells caused slight 
(about 4-fold) upregulation of CD34, CD41, CD44 and 
CD61.  
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Figure 5. Effect of Snail and Twist1 on induction of K562 differentiation: (A) Real-time PCR showing relative levels of γ−globin and β-actin in K562 cells 
treated with imatinib for 6 days. (B) Quantitative presentation of relative γ-globin levels (normalized to β-actin) as a marker for erythrocyte differentiation. (C) Flow 
cytometry analysis following CD41/CD61 in K562 cells treated with 5 ng/ml PMA for 6 days compared to untreated cells. (D) Quantitative levels of 
CD41/CD61-positive cells after exposure to PMA (1 ng/ml) for 6 days. Experiments were repeated twice with comparable outcome. 
 
Table 4. Effect of β-catenin in surface cell markers in 
K562 ectopically expressing Twist1 and Snail: K562 cells 
were incubated with 4-OHT for 2 weeks and expression levels of 
a variety of cluster of differentiations (CDs) were monitored by 
FACS. The experiment was performed twice with comparable 
outcomes. 
Cell β-catenin % of cells positive for 
CD61 CD41 CD34 CD44 
K562 
 
WT 1.2 0 0.2 0.5 
Silenced 5.3 0.1 1.5 5.3 
K562/Snail 
 
WT 16.8 0.6 6.8 18.1 
Silenced 0.8 0.1 0.2 0.5 
K562/Twist1 
 
WT 0.5 0.2 0.2 1.9 
 Silenced 0.8 0.1 0.1 0.5 
Discussion 
Expression of EMT modulators [33] such as 
Snail, Slug, and Twist1 has been implicated in the 
induction of mesenchymal and stemness markers in 
epithelial cells [34] [17]. Moreover, there are more and 
more reports demonstrating the ability of EMT 
modulators such as Snail to increase leukemia 
formation and radioprotection [35]. Others have 
implicated the Zeb2 EMT modulator in the 
differentiation of human stem cells and hematopoietic 
progenitor cells [10]. To elucidate potential signaling 
alterations in Ph+ leukemia cells, we monitored 
expression levels of the EMT modulators Snail, 
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Twist1, Slug and Zeb1 in Ph+ leukemia. Although 
their expression levels were correlated with the 
epithelial cells' transition to a mesenchymal 
phenotype, a few EMT modulators were also 
expressed in Ph+ leukemia cells at varying levels. 
Snail and Zeb1 were present in all Ph+ leukemia cells 
at comparable levels. Slug transcript was present at 
significant levels in MEG-01. Our hypothesis argues 
for functional significance of the EMT modulators in 
Ph+ leukemia and their possible involvement in 
mediating the EMT-like phenotype previously 
reported in leukemia cells, including Ph+ leukemia 
cells [13]. Moreover, the EMT-like process might be 
involved in the development of residual disease in 
Ph+ leukemia.  
Cell-surface receptors, and in particular CD44, 
have been implicated as key regulators of homing and 
engraftment of cancer cells to the BM stroma. 
Moreover, CD44 expression has been shown to 
increase in several types of leukemia as well as in 
K562 cells, and its level seems to influence 
proliferation and survival [36]. Thus, we monitored 
CD44 expression levels in cell lines of different types 
of Ph+ leukemia by RT-PCR and FACS analysis (Table 
1 and Figure 2). SupB15, BV173 and MEG-01 cell lines 
expressed high levels of CD44, in contrast to the K562 
cell line. Our data are in agreement with results 
obtained by Puissant et al. [13] demonstrating that 
long-time exposure of CML cells to imatinib causes a 
mesenchymal-like conversion accompanied by 
increased expression of mesenchymal markers such as 
Snail, Osteonectin, TBX3 and β-catenin, as well as 
CD44. 
 
 
 
Figure 6. Ectopic expression of Snail and Twist1 enhance adhesion to mesenchymal cells: (A) K562 and MEG-01 were transfected with Luciferase 
reporter plasmid and equal amounts of transfected cells were added to MS-5 pre-coated wells or empty wells. Wells were washed with PBS and levels of remaining 
luciferase levels were determined. (B) Comparing specific adhesion ability of transfected K562, K562/Twist1 and K562/Snail cells.  
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Figure 7. Effect of β-catenin on Snail-dependent CD44 expression. (A) Real-time PCR of β-catenin levels in wild type (WT) and β-catenin-silenced K562, 
K562/Snail and K562/Twist cell lines treated with 4-OHT for 2 weeks. (B) Levels of CD44 expression in K562 cells containing WT and silenced (Si) β-catenin as 
determined by FACS. (C) Quantitative representation of CD44 levels, as determined by FACS, in K562 cells containing WT β-catenin and Si β-catenin. (D) 
Quantitative representation of CD44 levels, as determined by real-time PCR, in K562 cells containing WT β-catenin and Si β-catenin. (E) FACS determination of 
expression levels of CD44 in PMA-induced WT and Si β-catenin K562 cells. (F) Quantitative representation of CD44 levels, as determined by FACS, of PMA-induced 
K562 cells in comparison to K562 Si β-catenin cells. Experiments in part E were performed twice with comparable outcomes, and the rest of the experiments in this 
figure were performed three times with comparable outcomes. *Significant difference at P < 0.01. 
 
A variety of soluble factors, and in particular 
TGF-β1, might take part in stimulating this EMT-like 
phenotype. TGF-β1 has been implicated as a regulator 
of EMT by upregulating levels of EMT modulators 
such as Snail, Twist1 and others [37]. Thus, we 
explored the possibility that EMT modulators such as 
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Snail and Twist1 might enhance CD44 expression in 
Ph+ leukemia cell lines. The K562 cell line was 
selected for this study because it contains minimal 
amounts of CD44. Our data demonstrated that ectopic 
expression of Snail, but not Twist1, significantly 
stimulates expression of CD44 as measured by 
real-time PCR and FACS analysis (Figure 4). In 
contrast, neither Snail nor Twist1 were effective at 
stimulating CXCR4 expression in K562 cells (Table 2). 
One of hallmarks of Ph+ leukemia is blockage of 
differentiation [27]. Thus, we explored the ability of 
PMA and imatinib to induce megakaryocyte and 
erythroid differentiation, respectively. Stimulation of 
γ-globin expression was used as a marker for 
erythroid differentiation [29]. Imatinib was effective at 
inducing γ-globin expression in K562 as well as 
K562/Snail cells (Figure 5) to comparable levels. 
However, ectopic expression of Twist1 significantly 
induced γ-globin expression to 2- to 3-fold the levels 
obtained from K562 and K562/Snail cells. Moreover, 
ectopic expression of Twist1 in K562 cells 
compromised PMA's ability to induce megakaryocyte 
differentiation by about 50% compared to the parental 
K562 cells. Taken together, our data show that the 
presence of Twist1 or Snail blocks K562 cells' ability to 
undergo megakaryocyte differentiation, which might 
explain the observed phenomenon of differentiation 
blockage in advanced stages of CML cells, which 
might be the cells that undergo the EMT-like 
transition.  
Although Ph+ leukemia cells that ectopically 
expressed Snail did not undergo a true EMT, they 
displayed an EMT-like phenotype [13], including 
enhanced expression of stem cell markers such as 
CD34 and CD117 [38]. An increased percentage of 
Ph+ leukemia cells that are positive for CD34 and also 
express c-kit (CD117) has been reported in 
non-responders to therapy and has been associated 
with an unfavorable outcome [39].  
The Wnt/β-catenin pathway has been implicated 
in controlling survival, self-renewal, and 
differentiation of human stem cells and hematopoietic 
progenitor cells [40]. Specifically, granulocyte- 
macrophage progenitors from CML patients and BC 
cells from patients who are resistant to therapy 
display activated Wnt signaling [41]. To explore the 
cross-talk between Snail and β-catenin in our model 
system, we silenced β-catenin in the K562 cell lines 
and monitored the effect on CD44 expression. CD44 
expression in K562/Snail cells was β-catenin- 
dependent (Figure 7). Interestingly, although MEG-01 
expressed endogenous CD44 at high levels (Figure 2 
and Table 1), silencing of β-catenin in this cell line 
(data not shown) did not cause any reduction in CD44 
levels, arguing that expression of CD44 in MEG-01 is 
independent  of β-catenin. A variety of signaling 
pathways have been reported to regulate CD44 
expression [32]. Moreover, PMA is well known to 
stimulate CD44 expression in a NF-κB-dependent 
manner [32]. Thus, we investigated the ability of PMA 
to stimulate CD44 expression (Figure 7E-F) and found 
that PMA-induced CD44 expression in K562 cells is 
independent of β-catenin.  
Taken together, Ph+ leukemia cells might 
acquire a mesenchymal-like phenotype in response to 
exposure to targeted therapy and/or growth factors 
such as TGF-β1 mediated by upregulation of EMT 
modulators. Conversion of Ph+ leukemia cells to a 
mesenchymal-like phenotype will accompanied by 
the upregulation of stemness factors such as 
CD34/CD117 and others, in addition to CD44, which 
also mediates BM homing, increased adhesion to 
stroma cells and engrafting and thus contributes to 
Ph+ leukemia residual disease.  
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